Overview

Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.
Phase:
Phase 2
Details
Lead Sponsor:
XOMA (US) LLC